GILD

132.90

0.29% -0.39

시간 외 거래: 132.88 -0.02 -0.02%

길리어드 사이언스 (GILD)

개요 뉴스 가격 이력 옵션 체인 Financials GILD 왜 하락? 토론 예측 주식 분할 배당 이력

전일 마감가:

$133.29

열려 있는:

$133.69

하루 거래량:

6.29M

Relative Volume:

0.91

시가총액:

$164.96B

수익:

$29.45B

순이익/손실:

$8.51B

주가수익비율:

19.60

EPS:

6.7823

순현금흐름:

$9.46B

1주 성능:

-4.92%

1개월 성능:

-3.14%

6개월 성능:

+9.42%

1년 성능:

+25.96%

1일 변동 폭

$131.34

$134.07

1주일 범위

$131.34

$140.26

52주 변동 폭

$93.37

$157.29

길리어드 사이언스 Stock (GILD) Company Profile

명칭

Gilead Sciences Inc

부문

Healthcare (1109)

산업

Drug Manufacturers - General (20)

전화

(650) 574-3000

주소

333 LAKESIDE DR, FOSTER CITY, CA

직원

17,000

트위터

@GileadSciences

다음 수익 날짜

2026-05-07

최신 SEC 제출 서류

GILD's Discussions on Twitter

Compare GILD vs LLY, JNJ, ABBV, AZN, NVS

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
GILD Gilead Sciences Inc	132.90	165.44B	29.45B	8.51B	9.46B	6.7823
LLY Lilly Eli Co	921.48	806.72B	65.18B	20.64B	5.96B	22.59
JNJ Johnson Johnson	226.10	544.73B	96.36B	21.04B	19.70B	8.6488
ABBV Abbvie Inc	200.50	362.81B	61.16B	4.19B	17.82B	2.3614
AZN Astrazeneca Plc	194.81	303.62B	58.80B	10.24B	8.98B	3.2788
NVS Novartis Ag Adr	147.32	282.35B	54.72B	14.02B	15.32B	7.1855

길리어드 사이언스 Stock (GILD) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2026-03-10	개시	Jefferies	Buy
2026-02-20	개시	Barclays	Equal Weight
2026-02-11	재확인	Needham	Buy
2026-01-07	재개	UBS	Buy
2025-11-24	재개	Truist	Buy
2025-11-13	개시	Scotiabank	Sector Outperform
2025-08-19	업그레이드	Daiwa Securities	Neutral → Outperform
2025-08-08	업그레이드	Truist	Hold → Buy
2025-07-25	업그레이드	Needham	Hold → Buy
2025-04-22	재개	Cantor Fitzgerald	Overweight
2025-03-04	재확인	Oppenheimer	Outperform
2025-02-18	업그레이드	Deutsche Bank	Hold → Buy
2025-02-13	업그레이드	DZ Bank	Hold → Buy
2025-01-10	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2024-12-10	재개	BofA Securities	Buy
2024-11-15	개시	Wolfe Research	Outperform
2024-11-14	개시	Citigroup	Buy
2024-11-08	다운그레이드	Maxim Group	Buy → Hold
2024-10-21	업그레이드	Leerink Partners	Market Perform → Outperform
2024-10-17	개시	Bernstein	Outperform
2024-10-07	업그레이드	Wells Fargo	Equal Weight → Overweight
2024-07-08	업그레이드	Raymond James	Mkt Perform → Outperform
2024-05-01	재확인	Maxim Group	Buy
2024-04-24	업그레이드	HSBC Securities	Reduce → Hold
2024-02-22	다운그레이드	Truist	Buy → Hold
2023-11-09	개시	Deutsche Bank	Hold
2023-09-08	업그레이드	BofA Securities	Neutral → Buy
2023-09-06	개시	HSBC Securities	Reduce
2023-07-24	재확인	Barclays	Equal Weight
2023-05-16	업그레이드	BMO Capital Markets	Market Perform → Outperform
2023-04-28	재개	Piper Sandler	Overweight
2023-01-03	다운그레이드	RBC Capital Mkts	Outperform → Sector Perform
2022-12-13	재개	BofA Securities	Neutral
2022-12-09	다운그레이드	DZ Bank	Buy → Hold
2022-10-31	업그레이드	Barclays	Underweight → Equal Weight
2022-10-28	재확인	BMO Capital Markets	Market Perform
2022-10-28	재확인	Cowen	Outperform
2022-10-28	재확인	JP Morgan	Overweight
2022-10-28	재확인	Jefferies	Buy
2022-10-28	업그레이드	Piper Sandler	Neutral → Overweight
2022-10-28	재확인	RBC Capital Mkts	Outperform
2022-10-28	업그레이드	Truist	Hold → Buy
2022-10-28	재확인	Wells Fargo	Equal Weight
2022-10-04	업그레이드	JP Morgan	Neutral → Overweight
2022-07-13	개시	Cantor Fitzgerald	Neutral
2022-05-23	개시	SVB Leerink	Mkt Perform
2022-02-28	다운그레이드	BMO Capital Markets	Outperform → Market Perform
2022-02-02	재확인	BMO Capital Markets	Outperform
2022-02-02	재확인	BofA Securities	Neutral
2022-02-02	재확인	RBC Capital Mkts	Outperform
2022-02-02	재확인	Truist	Hold
2022-02-02	재확인	Wells Fargo	Equal Weight
2022-01-28	업그레이드	Argus	Hold → Buy
2022-01-06	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2021-12-09	재개	Wells Fargo	Equal Weight
2021-12-06	개시	Goldman	Neutral
2021-11-19	업그레이드	BMO Capital Markets	Market Perform → Outperform
2021-11-19	재개	Piper Sandler	Neutral
2021-10-20	재개	Cowen	Outperform
2021-07-30	재확인	BMO Capital Markets	Market Perform
2021-07-30	재확인	RBC Capital Mkts	Outperform
2021-04-01	업그레이드	Bernstein	Mkt Perform → Outperform
2021-03-30	업그레이드	Redburn	Neutral → Buy
2021-01-19	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2021-01-04	업그레이드	Guggenheim	Neutral → Buy
2020-11-03	재개	Morgan Stanley	Equal-Weight
2020-10-28	개시	UBS	Neutral
2020-09-30	재개	Jefferies	Buy
2020-09-15	업그레이드	Maxim Group	Hold → Buy
2020-07-31	재확인	Credit Suisse	Neutral
2020-07-31	재확인	Morgan Stanley	Equal-Weight
2020-07-31	재확인	Piper Sandler	Overweight
2020-07-31	재확인	RBC Capital Mkts	Outperform
2020-07-31	재확인	SunTrust	Hold
2020-07-31	재확인	Wells Fargo	Equal Weight
2020-07-20	업그레이드	Credit Suisse	Underperform → Neutral
2020-06-03	업그레이드	SVB Leerink	Mkt Perform → Outperform
2020-05-26	업그레이드	SunTrust	Sell → Hold
2020-05-01	다운그레이드	JP Morgan	Overweight → Neutral
2020-05-01	다운그레이드	Raymond James	Outperform → Mkt Perform
2020-05-01	다운그레이드	SunTrust	Hold → Sell
2020-04-27	다운그레이드	UBS	Buy → Neutral
2020-04-20	다운그레이드	BMO Capital Markets	Outperform → Market Perform
2020-04-20	다운그레이드	Wells Fargo	Overweight → Equal Weight
2020-04-17	다운그레이드	CFRA	Hold → Sell

모두보기

길리어드 사이언스 주식(GILD)의 최신 뉴스

Apr 22, 2026

FDA Nod for Merck HIV Drug Brings Competition to a Gilead Sciences Antiretroviral - MedCity News

Apr 22, 2026

Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026 - Yahoo Finance UK

Apr 22, 2026

GILD (Gilead Sciences Inc.) reports narrow Q4 2025 earnings beat and mild revenue growth, shares dip slightly.Open Stock Signal Network - Cổng thông tin điện tử Tỉnh Sơn La

Apr 22, 2026

Gilead Sciences stock price forecast: limited upside as GILD trades near support after weekly decline - Traders Union

Apr 22, 2026

Gilead set to report as Yeztugo launch, M&A strategy face test - Investing.com India

Apr 22, 2026

Universal Beteiligungs und Servicegesellschaft mbH Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat

Apr 22, 2026

Merck steps up as ‘meaningful competitor’ to Gilead with HIV pill approval - BioSpace

Apr 22, 2026

Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026 - GlobeNewswire Inc.

Apr 22, 2026

Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Weakness And Long Term Gains - simplywall.st

Apr 22, 2026

Apr 21, 2026

Gilead Sciences Inc. stock outperforms competitors despite losses on the day - MarketWatch

Apr 21, 2026

Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now? - Yahoo Finance

Apr 21, 2026

Release of 2025 impact report weighs on Gilead Sciences stock amid oversold momentum signals - Traders Union

Apr 21, 2026

Gilead Sciences Deploys $16 Billion in 60 Days: Is GILD Stock Undervalued for 2026? - TIKR.com

Apr 21, 2026

7,568 Shares in Gilead Sciences, Inc. $GILD Acquired by Ticino Wealth - MarketBeat

Apr 21, 2026

Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls - BioSpace

Apr 21, 2026

Gilead Sciences : Publishes 2025 Responsible Business and Impact Report, Highlighting Momentum Toward 2030 Ambitions - marketscreener.com

Apr 21, 2026

Arcus pulls another TIGIT trial as Gilead steps back - The Pharma Letter

Apr 21, 2026

Zacks Research Predicts Lower Earnings for Gilead Sciences - MarketBeat

Apr 21, 2026

Gilead Sciences, Inc. (GILD) Stock Analysis: A Healthcare Giant with a 15% Upside Potential - DirectorsTalk Interviews

Apr 21, 2026

Apr 20, 2026

Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors - Yahoo Finance

Apr 20, 2026

Lobbying Update: $3,190,000 of GILEAD SCIENCES INC lobbying was just disclosed - Quiver Quantitative

Apr 20, 2026

Gilead Sciences: Why I'm Tempted To Sell Ahead Of Q1 EarningsBut Won't (NASDAQ:GILD) - Seeking Alpha

Apr 20, 2026

Leerink cuts Arcus Biosciences stock price target on Gilead collaboration end - Investing.com Canada

Apr 20, 2026

Gilead Sciences stock edges lower as company discusses expanding oncology reach at AACR26 - Traders Union

Apr 20, 2026

Arcus halts Gilead-partnered late-stage trial (RCUS:NYSE) - Seeking Alpha

Apr 20, 2026

Arcus Ends Key Lung Cancer Trials in Gilead Partnership Reset - TipRanks

Apr 20, 2026

Arcus Biosciences ends STAR-121 lung cancer study and updates Gilead collaboration - Investing.com

Apr 20, 2026

Arcus Biosciences Incdiscontinues phase 3 star-121 study with Gilead due to futility - marketscreener.com

Apr 20, 2026

Zurcher Kantonalbank Zurich Cantonalbank Purchases 19,741 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Apr 20, 2026

Gilead Sciences, Inc. $GILD Stake Lowered by Miller Howard Investments Inc. NY - MarketBeat

Apr 20, 2026

Gilead Sciences (NASDAQ:GILD): A Value Screen Candidate with Strong Profitability - ChartMill

Apr 20, 2026

Apr 19, 2026

Gilead Sciences to buy clinical-stage biotech Tubulis for up to $5 billion - MSN

Apr 19, 2026

Gilead Sciences, Inc. (GILD) is a trending stock: Facts to know before betting on it - MSN

Apr 19, 2026

Gilead Deepens Oncology Reach And HIV Prevention With Arcellx And Lenacapavir - Yahoo Finance

Apr 19, 2026

Gilead Sciences, Inc. $GILD Shares Acquired by AE Wealth Management LLC - MarketBeat

Apr 19, 2026

Apr 18, 2026

Gilead Sciences, Inc. $GILD Shares Bought by GF Fund Management CO. LTD. - MarketBeat

Apr 18, 2026

Gilead Sciences, Inc. $GILD Position Raised by Asset Management One Co. Ltd. - MarketBeat

Apr 18, 2026

Apr 17, 2026

Wall Street Analysts Are Neutral on Top Healthcare Picks - The Globe and Mail

Apr 17, 2026

Citi Raises Gilead (GILD) Price Target Ahead of Q1 Biopharma Preview - Insider Monkey

Apr 17, 2026

Jim Cramer on Gilead Sciences: “I’d Hold On to It” - Insider Monkey

Apr 17, 2026

Gilead Sciences stock edges lower as research teams attend AACR26 to advance cancer therapies - Traders Union

Apr 17, 2026

Gilead (GILD) Extends Tender Offer for Arcellx (ACLX) to April 2 - GuruFocus

Apr 17, 2026

Gilead extends Arcellx tender offer again - MSN

Apr 17, 2026

Gilead Sciences (NASDAQ:GILD) Given New $130.00 Price Target at The Goldman Sachs Group - MarketBeat

Apr 17, 2026

Morgan Stanley Adjusts Gilead Sciences, Inc. (GILD) Outlook Ahead of Q1 Earnings - Insider Monkey

Apr 17, 2026

Goldman Sachs Adjusts Gilead Sciences Price Target to $130 From $125, Maintains Neutral Rating - Moomoo

Apr 17, 2026

Gilead extends Arcellx tender offer again (GILD:NASDAQ) - Seeking Alpha

Apr 17, 2026

Gilead Sciences (NASDAQ: ACLX) offers $115 per share plus CVR; deadline extended - Stock Titan

Apr 17, 2026

Gilead Sciences patents new GTPase KRAS G12D inhibitors - BioWorld News

Apr 17, 2026

Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $155 From $115, Maintains Overweight Rating - Moomoo

Apr 17, 2026

Gilead extends Arcellx tender offer to April 27 - Investing.com

Apr 17, 2026